Antiviral agents for prevention and/or treatment of influenza virus infections: old and new by Feldman, C
Epidemics of influenza A and/or B typical-
ly occur every year during the winter
months and are a cause of considerable
morbidity and even mortality worldwide.1,2
While influenza may occur at any age, it is
more frequent in children and more seri-
ous in the elderly, the latter because of the
presence of underlying diseases that are
associated with more complicated infec-
tion.1
Influenza is spread from person to person
by sneezing and coughing.1 The incuba-
tion period is short, usually 1 - 4 days,
with an average of 2 days. Patients are
infectious from the day before the onset of
symptoms until 5 days after symptoms
start. Uncomplicated influenza is charac-
terised by the abrupt onset of constitu-
tional and respiratory symptoms and
signs. On the basis of symptoms alone,
respiratory illness due to influenza is diffi-
cult to distinguish from illness caused by a
wide range of other respiratory pathogens.
Ideally, therefore, a definitive laboratory
diagnosis of influenza would be used to
guide the use of antiviral agents. In prac-
tice, laboratory confirmation by rapid
shell vial culture has a 48-hour turn-
around time, which exceeds the window
of opportunity for instituting anti-influen-
za therapy in an individual patient.
Routine laboratory surveillance for
influenza in major centres can provide
information on community influenza
activity and allow a presumptive diagnosis
of influenza in an individual when com-
munity activity is high.
Symptoms of infection usually resolve in a
limited number of days in most individu-
als. In some cases exacerbation of prior
co-morbid conditions (cardiac and respi-
ratory) may occur and influenza can cause
primary viral pneumonia or lead to sec-
ondary bacterial pneumonia. A number of




The main option for the prevention of
influenza and its complications is yearly
vaccination with the appropriate formula-
tion of inactivated vaccine (killed vaccine)
before the seasonal increases in influenza
virus circulation.1 Antiviral agents are an
adjunct to vaccination for the control and
prevention of influenza infection, but
should never be used as a substitute for
vaccination.1 Two different classes of
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Antiviral agents for preven-
tion and/or treatment of
influenza virus infections:
old and new
Influenza continues to be a cause of significant
morbidity and mortality around the world each
year, but advances in its treatment and prophy -
laxis mean that it no longer needs to be such a
headache for the GP.
MAIN TOPIC
318 C M E J un e  2 0 0 3   Vo l . 2 1   N o . 6
Uncomplicated influenza
is characterised by the
abrupt onset of constitu -
tional and respiratory
symptoms and signs. 
antiviral agents are available, the
adamantanes (older agents) and
the neuraminidase inhibitors
(newer agents). In South Africa ,
only one of the adamantanes (aman-
tadine) and one of the neuraminidase
i n h i b i t o rs (zanamivir) are curr e n t l y
licensed for use. H owe ve r , for com-
p l e t e n e s s , all the different agents will
be discussed below.
Adamantanes1-5
These agents were described more
than 30 years ago. Amantadine and
rimantadine are chemically related
antiviral agents that are active
against influenza A virus, but not
against influenza B virus. Both
agents are administered orally and
rimantadine is better tolerated.
They act by blocking the M2 pro-
tein channels of influenza A virus.
Once influenza A is taken up into a
cell through receptor-mediated
endocytosis, the M2 channel’s
hydrogen ion transport function
ordinarily facilitates acidification of
the virus’s interior, a process essen-
tial for viral uncoating and release
of the nucleic acid for transcription
and translation. Adamantanes
therefore prevent uncoating of the
virus, and this is inhibitory to viral
replication.
These agents are about 70 - 90%
effective as prophylaxis against
influenza A infections. Also, when
administered within 48 hours of
onset of illness, they can reduce
the duration of uncomplicated
influenza A virus infection.They
have not been clearly demonstrated
to be effective in preventing serious
influenza-related complications.
Moreover, most studies of the ben-
efit of all the antiviral agents have
been conducted in uncomplicated
influenza.When used as prophylax-
is, they may also prevent illness
while permitting subclinical infec-
tion and the development of pro-
tective antibodies against circulat-
ing influenza virus. This means that
some patients on prophylaxis with
these agents will develop protective
immune responses to the virus.
They also do not interfere with the
antibody response to the vaccine.
One problem with the use of the
adamantanes is the potential for
rapid development of influenza
virus resistance. To reduce the
emergence of resistance, these
agents should be discontinued as
soon as clinically warranted, which
is typically 3 - 5 days after initia-
tion of therapy or 24 - 48 hours
after disappearance of symptoms/
signs.
Dosage recommendations vary
according to age and associated
medical conditions (Table I).
Both the adamantane agents can
cause central nervous system
(CNS) and gastrointestinal (GIT )
side-effects. The CNS side-effects
include nervousness, anxiety,
insomnia, difficulty in concentrat-
ing and light-headedness. It is rec-
ommended that patients with
seizure disorders be observed care-
fully during treatment. Amantadine
should be used with caution when
administered concurrently with
drugs that affect the CNS, particu-
larly stimulants. Concurrent
administration of antihistamines
and anticholinergics increases the
risk of adverse CNS reactions. GIT
side-effects include nausea and
anorexia. Side-effects are usually
mild and stop soon after the drugs
are discontinued. Because amanta-
dine has anticholinergic effects, it
should not be given to anyone with
untreated angle closure glaucoma.
In acute overdose of amantadine,
CNS, renal, respiratory and car-
diac side-effects, including arrhyth-
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Drug Subject Dose
Amantadine*/rimantadine† adult 100 mg bd
adult > 65 yrs 50 mg bd or lower
child 1 - 9 yrs (< 40 kg) 5 mg/kg/day (max. 150 mg)
divided into bd dosages
child ≥ 10 yrs (> 40 kg) 100 mg bd
Zanamivir adult 10 mg (2 inhalations) bd
(once daily for prophylaxis)
child ≥ 12 yrs 10 mg (2 inhalations) bd
(once daily for prophylaxis)
Oseltamivir* adult 75 mg bd
(once daily for prophylaxis)
child ≥ 13 yrs 75 mg bd
(once daily for prophylaxis)
child 1 - 12 yrs (< 40 kg) < 15 kg: 30 mg bd
16 - 23 kg: 45 mg bd
24 - 40 kg: 60 mg bd
* Dosage adjustment advised for impaired renal function.
† Dosage adjustment advised for impaired renal or hepatic function.
Table I. Treatment and prophylaxis dosages for anti-influenza drugs
mias, have been noted. No studies
have been undertaken regarding
their safety in pregnant women.
Both amantadine and rimantadine
have been shown to be teratogenic
and embryotoxic in large doses in
animal studies.
Neuraminidase inhibitors1-4,6-8
Viral neuraminidase, a surface gly-
coprotein of influenza A and B,
aids the release of newly formed
virus particles from infected cells.
Neuraminidase may also counter-
act viral inactivation by respiratory
mucus, thus facilitating cell-to-cell
spread of the virus. Neuraminidase
inhibitors block the activity of neu-
raminidase and selectively reduce
the replication of influenza A and
B viruses.
Zanamivir and oseltamivir are
chemically related antiviral agents,
known as neuraminidase
inhibitors, which have activity
against both influenza A and B.
Oseltamivir is administered orally
and zanamivir by oral inhalation.
These agents can reduce the dura-
tion of uncomplicated infection by
approximately 1-2.5 days com-
pared with placebo. However, they
have not been shown to be effec-
tive in preventing serious influen-
za-related complications. Both
agents are effective in preventing
febrile, laboratory-confirmed
influenza illness and have been
reported to be effective as prophy-
laxis after a household member has
been diagnosed as having influenza.
Zanamivir has been approved in
South Africa for the treatment of
people ≥ 12 years of age.
Oseltamivir has been approved in
the USA (but has not been
licensed yet in South Africa) for
treatment of children ≥ 1 year of
age and for chemoprophylaxis of
anyone ≥ 13 years (see Table I for
neuraminidase inhibitor dosages).
In some studies, zanamivir was
associated with respiratory symp-
toms, including airway hyperre-
sponsiveness and/or deterioration
of lung function, including a
decrease in FEV1 of > 20%, partic-
ularly in patients with asthma or
obstructive airway disease.
Subsequently zanamivir was shown
to be safe and beneficial in patients
with asthma and chronic obstruc-
tive pulmonary disease.
Nonetheless, all patients with air-
way disorders taking this agent
should have a fast-acting bron-
chodilator available. Other side-
effects noted with both these
agents have been relatively uncom-
mon. No clinical studies have been
undertaken of safety in pregnant
women.Very limited clinical data
are available about drug interac-
tions with these agents.
Anti-influenza drugs as chemo-
prophylaxis1-3,9,10
Factors such as cost, compliance,
and side-effects need to be consid-
ered when determining the agent
of choice, timing and duration of
therapy.To be maximally effective
the drugs should be taken daily for
the entire duration of the influenza
season; however, to be more cost
effective, one study of amantadine
or rimantadine prophylaxis sug-
gested that these drugs should be
taken only during the period of
peak influenza activity. Individuals
who should be considered for pro-
phylaxis include the following:
• Persons at high risk who have
not been vaccinated or are vac-
cinated after influenza activity
has begun. Persons at high risk
of influenza complications can
still be vaccinated after an out-
break of influenza has begun.
Since the development of anti-
bodies takes approximately 2
weeks, high-risk cases could
receive prophylaxis from the
time of vaccination until anti-
bodies develop.
• Unvaccinated persons who pro-
vide care to those at high risk.
To reduce the spread of the
virus to persons at high risk dur-
ing community or institutional
outbreaks, those who provide
care and are unvaccinated could
receive prophylaxis.They
include employees of hospitals,
clinics, and chronic-care facili-
ties, household members, dis-
trict nurses, and volunteer work-
ers.
• Persons who have immune defi-
ciency. Chemoprophylaxis could
be considered for persons with
immune deficiency, who may be
expected to have an inadequate 
antibody response after vaccina-
tion.
• Persons in whom vaccination is
contraindicated (e.g. those with
severe hypersensitivity to egg
protein). Chemoprophylaxis
throughout the influenza season
or during peak viral activity
could be considered for high-
risk cases who should not be
vaccinated.
• Other persons wishing to pre-
vent infection with influenza
(e.g. persons who are to travel
from one area to another, such
as from the southern hemi-
sphere to the northern hemi-
sphere).
Control of institutional out-
breaks of influenza1,9
Use of antiviral agents is a key
component in the treatment and
prevention of institutional out-
breaks of influenza infection, and is
combined with other outbreak con-
trol measures. Most published
studies have reported on influenza
A outbreaks among nursing home
populations using the adaman-
tanes. Less information is available
on the neuraminidase inhibitors
and influenza A or B outbreaks.
According to the Centers for
Disease Control and Prevention,
Atlanta, USA, during outbreaks
chemoprophylaxis should be given
to all residents irrespective of their
vaccination status for ≥ 2 weeks. If
surveillance indicates ongoing
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occurrence of new infections, pro-
phylaxis should be continued until
1 week after the last infection.
Chemoprophylaxis can also be
offered to unvaccinated staff look-
ing after persons at high risk. In
addition to nursing homes, similar
recommendations are made for
control of outbreaks in closed or
semi-closed settings, such as dor-
mitories or large businesses. These
agents have also been used for con-
trol of household outbreaks of
influenza infection.
References available on request.
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IN A NUTSHELL
Yearly epidemics of influenza are a
cause of considerable morbidity
and mortality worldwide.
Influenza vaccination is the prima-
ry means of prevention of infection
and its complications.
Antiviral agents are an adjunct to
vaccination for control and preven-
tion of influenza infection, but
should never be used as a substi-
tute for vaccination.
Two classes of antiviral agents are
available for the prevention and
treatment of influenza infection,
the adamantanes and the neu-
raminidase inhibitors.
Adamantanes block the M2 pro-
tein channels of the influenza A
virus and prevent uncoating of the
virus inside the cells, so inhibiting
replication.
The neuraminidase inhibitors block
the activity of viral neuraminidase,
so preventing the release of newly
formed viruses from cells.
Amantadine, an adamantane avail -
able in South Africa, is 70 - 90%
effective in preventing illness
caused by influenza A infection,
and when administered within 2
days of onset of illness can reduce
the duration of uncomplicated
influenza A infection.
